# FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)

> **NCT02661971** · PHASE2,PHASE3 · COMPLETED · sponsor: **Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest** · enrollment: 180 (actual)

## Conditions studied

- Stomach Cancer
- Gastroesophageal Junction Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Oxaliplatin
- **DRUG:** Calciumfolinat
- **DRUG:** 5-Fluorouracil
- **BIOLOGICAL:** Ramucirumab

## Key facts

- **NCT ID:** NCT02661971
- **Lead sponsor:** Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2021-12
- **Final completion:** 2022-06-20
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2022-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02661971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02661971, "FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02661971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*